services

Companion and Complimentary Diagnostics Companion diagnostics continue to play an ever expanding role in personalized healthcare as physician’s seek to better more accurately forecast patients’ potential responses to various treatment options. Whether you are a pharmaceutical company embarking on a new drug/Companion diagnostic offering or an independent Companion diagnostic manufacturer, our team can provide unparalled support to ensure expedient and successful parallel development of both your companion test and drug/biologic.

Mutation Analysis: Single Nucleotide Poloymorphism (SNP) Mutations are genetic alterations either in germ or non-germ (somatic) cells. Mutations can impact the formation of various diseases as well as affect the response of a patient to particular drug treatments. The mutation can be an insertion, deletion, missense or nonsense mutation in the coding or non-coding regions. In some cases, a mutation occurs at the intron-exon boundary and affects the normal splicing of the transcript.

Gene Expression Services Scientists at Genome Explorations have worked with over 350 scientists worldwide in meeting their gene expression needs. As an industry leader in the microarray field and a certified provider of Affymetrix® microarray services and Life Technologies qPCR services, we have developed a series of SOPs that allow us to reproducibly generate global gene expression data sets of the highest quality. Our validated microarray protocols consistently result in sample-to-sample variability of less than 0.

DEFINE, DESIGN, DISCOVER Our experienced scientists work one-on-one with scientists, researchers and clinicians to provide a ‘Complete Solution’ for Genotyping, Gene Expression and miRNA Profiling Services, from experimental design to in-depth data analysis and advanced bioinformatics. Our ‘Complete Solutions’ include state of the art Technologies from Illumina, Thermofisher Scientific and Affymetrix for challenging specimens, such as LCM, FFPE and whole blood samples. With over 40 years of combined experience, our scientists at Genome Explorations have developed detailed standard operating procedures (SOPs) that allow us to consistently generate the highest quality, most reproducible data sets in the industry.

Predict, Prepare, Prevent! As research continues to gain new insight into the role of genes in various diseases, including cancer, we now have the ability to test for certain genes known to increase risks for birth defects, cancers, heart disease, and many other maladies. Identification of predisposition mutations allow a proactive approach to inform the decision making process, proactively assess treament options, and help reduce the risk of developing a deadly disease later in life.

Detect, Characterize. Genomic research continues to identify mutations associated with specific cancers and, in combination with clinical research, to identify their clinical relevance to a specific cancer and the prognosis/treatment for patients. While some mutations may be pathogenic, some are benign. Mutation profiling allows us to identify which mutations are present, determine clinical significance of those mutations, and identify pathogentic mutations with actionable therapies. To this end, mutation profiling using next generation sequencing and targeted cancer-specific panels allows us to detect mutations across multiple genes simultaneously and to screen patient susceptibility to a specific cancer.

Targeted Cancer, Targeted SOLUTIONS. Through genomic research, we continue to learn more about the complexity of cancer. While cancer continues to be identified by its location in the body (lung, breast, blood, etc.), we have learned that a more accurate way to evaluate cancer treatment is through examination of the underlying changes or mutations which drive cancer development and progression. Those mutations are not limited to location and, in many instances, have very little correlation with the location.

ESSENTIAL Diagnostics. ACTIONABLE Results. Today, we know more about the impact of genomic variation upon onset and progression of disease than ever before. Years of research and strategic collaboration have allowed Genome Explorations to develop profiles designed to aid clinicians in their effort to harness information provided by the genetics of individual patients. Our profiles allow clinicians to evaluate key “trigger” genetic abnormalities, genetic considerations pertaining to certain locations within the body, or genes typically associated with family history of disease.